Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative PCSK9 inhibitor therapy in CABG
ChiCTR2500109222Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of tolelsimab in coronary arteriosclerosis (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: Epicardial adipose tissue volume and density and Coronary atherosclerotic plaque volume. Started Sep 2025; status: recruiting.
02
Drugs
tolelsimab
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500109222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109222.